Redeye presents its preview for Devyser’s Q2 2025 report, due on July 22.
Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.
Redeye updates its base case of Synact following the directed share issue and new programme in polym...
Ahead of Elanders' Q2 2025 report, we lower adjusted EBITA by 2-5% for 2025E-27E, as we take a sligh...
Q2e: -4.5% organic sales growth, 9% adj. EBITA margin Expect continued caution in Sweden Trading at ...
Redeye comments on IRLAB’s announcement of a guaranteed SEK 136m rights issue aimed at advancing its...
Redeye comments on IRLAB’s announcement of a fully guaranteed SEK 136m rights issue aimed at advanci...
Redeye thinks the phase II study is now on track, with the last patient recruited and preliminary re...
Redeye comments on today’s mandatory offer from Arise’s largest shareholder, the CA Group.
Cardeon, som investerar i Life Science-bolag i tidig utvecklingsfas, avser att genomföra ett förvärv...
Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre...
Forward-looking metrics a bit on the soft side Competitor and peer Accenture reported its Q3'25 repo...
CapMan has acquired the majority (51%) of German based real estate debt specialist CAERUS Debt Inves...
Redeye re-initiates coverage of marketing technology company Eniro Group, perceiving the company to ...
Redeye provides a comment on Verve’s announcement of a directed share issue which strengthens the co...
